Exome Asset Management LLC Bei Gene, Ltd. Transaction History
Exome Asset Management LLC
- $146 Billion
- Q3 2024
A detailed history of Exome Asset Management LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Exome Asset Management LLC holds 15,300 shares of BGNE stock, worth $2.91 Million. This represents 2.36% of its overall portfolio holdings.
Number of Shares
15,300
Previous 33,200
53.92%
Holding current value
$2.91 Million
Previous $4.74 Billion
27.48%
% of portfolio
2.36%
Previous 4.22%
Shares
4 transactions
Others Institutions Holding BGNE
# of Institutions
250Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.01 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.23 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$986 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$948 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$706 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.8B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...